

# Dihydroergotamine Mesylate Injection

## Safety Data Sheet

### SECTION 1: Identification

#### 1.1. Identification

Product name : Dihydroergotamine Mesylate Injection

#### 1.2. Relevant identified uses of the substance or mixture and uses advised against

Use of the substance/mixture : Pharmaceutical

#### 1.3. Details of the supplier of the safety data sheet

Apollo Pharmaceuticals USA Inc.  
4400 PGA Blvd. Suite 102  
Palm Beach Gardens, FL 33410

#### 1.4. Emergency telephone number

Emergency number : 833-727-6556 (833-7APOLLO)

### SECTION 2: Hazard(s) identification

#### 2.1. Classification of the substance or mixture

##### GHS US classification

Repr. 1B H360

Full text of hazard classes and H-statements : see section 16

#### 2.2. Label elements

##### GHS US labeling

Hazard pictograms (GHS US) :



GHS08

Signal word (GHS US) :

Danger

Hazard statements (GHS US) :

H360 - May damage fertility or the unborn child

Precautionary statements (GHS US) :

P201 - Obtain special instructions before use.  
P202 - Do not handle until all safety precautions have been read and understood.  
P280 - Wear protective gloves/protective clothing/eye protection/face protection.  
P308+P313 - If exposed or concerned: Get medical advice/attention.  
P405 - Store locked up.  
P501 - Dispose of contents/container to hazardous or special waste collection point, in accordance with local, regional, national and/or international regulation.

#### 2.3. Other hazards

No additional information available

#### 2.4. Unknown acute toxicity (GHS US)

Not applicable

### SECTION 3: Composition/Information on ingredients

#### 3.1. Substances

Not applicable

#### 3.2. Mixtures

Name	Product identifier	%	GHS US classification
Dihydroergotamine mesilate	(CAS-No.) 6190-39-2	< 1	Acute Tox. 4 (Oral), H302 Acute Tox. 4 (Dermal), H312 Acute Tox. 4 (Inhalation), H332 Skin Irrit. 2, H315 Eye Irrit. 2, H319 Repr. 1B, H360 STOT SE 3, H335

# Dihydroergotamine Mesylate Injection

## Safety Data Sheet

Full text of hazard classes and H-statements : see section 16

### SECTION 4: First aid measures

#### 4.1. Description of first aid measures

- First-aid measures after inhalation : If aerosols of this product are inhaled, remove victim to fresh air. The contaminated individual must seek medical attention if any adverse effects occur.
- First-aid measures after skin contact : If contact with this product results in adverse effect, flush affected area with water. Minimum flushing is for 20 minutes. The contaminated individual must seek medical attention if any adverse effects occur after flushing.
- First-aid measures after eye contact : If this product enters the eyes, open contaminated individual's eyes while under gently running water. Use sufficient force to open eyelids. Have contaminated individual "roll" eyes. Minimum flushing is for 20 minutes. Contaminated individual must seek medical attention if adverse effect occurs or continues after flushing.
- First-aid measures after ingestion : Seek immediate medical attention.

#### 4.2. Most important symptoms and effects, both acute and delayed

- Symptoms/effects after inhalation : May cause breathing difficulties if inhaled.
- Symptoms/effects after skin contact : May cause skin irritation.
- Symptoms/effects after eye contact : May cause eye irritation.
- Symptoms/effects after ingestion : May be harmful if swallowed.

#### 4.3. Indication of any immediate medical attention and special treatment needed

No additional information available

### SECTION 5: Firefighting measures

#### 5.1. Extinguishing media

- Suitable extinguishing media : Use extinguishing media appropriate for surrounding fire.
- Unsuitable extinguishing media : None.

#### 5.2. Special hazards arising from the substance or mixture

- Fire hazard : None known.

#### 5.3. Advice for firefighters

- Protection during firefighting : Firefighters should wear full protective gear.

### SECTION 6: Accidental release measures

#### 6.1. Personal precautions, protective equipment and emergency procedures

- General measures : No special measures required.

##### 6.1.1. For non-emergency personnel

No additional information available

##### 6.1.2. For emergency responders

No additional information available

#### 6.2. Environmental precautions

Prevent entry to sewers and public waters.

#### 6.3. Methods and material for containment and cleaning up

- For containment : Stop the flow of material, if this is without risk.

#### 6.4. Reference to other sections

No additional information available

### SECTION 7: Handling and storage

#### 7.1. Precautions for safe handling

- Precautions for safe handling : Do not eat, drink or smoke when using this product.

#### 7.2. Conditions for safe storage, including any incompatibilities

- Storage conditions : Keep container tightly closed. Store at 20° to 25°C (68° to 77°F). Do not refrigerate or freeze.

# Dihydroergotamine Mesylate Injection

## Safety Data Sheet

### SECTION 8: Exposure controls/personal protection

#### 8.1. Control parameters

##### Dihydroergotamine mesilate (6190-39-2)

Not applicable

#### 8.2. Exposure controls

Appropriate engineering controls	: Local exhaust and general ventilation must be adequate to meet exposure standards.
Hand protection	: Use neoprene or rubber gloves.
Eye protection	: In case of dust production: protective goggles.
Skin and body protection	: Wear suitable working clothes.
Respiratory protection	: If airborne concentrations are above the applicable exposure limits, use NIOSH approved respiratory protection.

### SECTION 9: Physical and chemical properties

#### 9.1. Information on basic physical and chemical properties

Physical state	: Liquid
Appearance	: Clear.
Color	: Colorless
Odor	: Odorless
Odor threshold	: No data available
pH	: No data available
Melting point	: No data available
Freezing point	: No data available
Boiling point	: No data available
Flash point	: No data available
Relative evaporation rate (butyl acetate=1)	: No data available
Flammability (solid, gas)	: No data available
Vapor pressure	: No data available
Relative vapor density at 20 °C	: No data available
Relative density	: No data available
Solubility	: Soluble.
Partition coefficient n-octanol/water (Log Pow)	: No data available
Auto-ignition temperature	: No data available
Decomposition temperature	: No data available
Viscosity, kinematic	: No data available
Viscosity, dynamic	: No data available
Explosion limits	: No data available
Explosive properties	: No data available
Oxidizing properties	: No data available

#### 9.2. Other information

No additional information available

### SECTION 10: Stability and reactivity

#### 10.1. Reactivity

No additional information available

#### 10.2. Chemical stability

The product is stable at normal handling and storage conditions.

#### 10.3. Possibility of hazardous reactions

Will not occur.

#### 10.4. Conditions to avoid

None.

# Dihydroergotamine Mesylate Injection

## Safety Data Sheet

### 10.5. Incompatible materials

None known.

### 10.6. Hazardous decomposition products

None known.

## SECTION 11: Toxicological information

### 11.1. Information on toxicological effects

Acute toxicity : Not classified

Dihydroergotamine mesilate (6190-39-2)	
LD50 oral rat	> 2 g/kg
ATE US (oral)	500 mg/kg body weight
ATE US (dermal)	1100 mg/kg body weight
ATE US (gases)	4500 ppmV/4h
ATE US (vapors)	11 mg/l/4h
ATE US (dust, mist)	1.5 mg/l/4h

Skin corrosion/irritation : Not classified

Serious eye damage/irritation : Not classified

Respiratory or skin sensitization : Not classified

Germ cell mutagenicity : Not classified

Carcinogenicity : Not classified

Reproductive toxicity : May damage fertility or the unborn child.

Specific target organ toxicity – single exposure : Not classified

Specific target organ toxicity – repeated exposure : Not classified

Aspiration hazard : Not classified

## SECTION 12: Ecological information

### 12.1. Toxicity

No additional information available

### 12.2. Persistence and degradability

No additional information available

### 12.3. Bioaccumulative potential

No additional information available

### 12.4. Mobility in soil

No additional information available

### 12.5. Other adverse effects

No additional information available

## SECTION 13: Disposal considerations

### 13.1. Waste treatment methods

Product/Packaging disposal recommendations : Dispose of contents/container in accordance with local/regional/national/international regulations.

## SECTION 14: Transport information

### Department of Transportation (DOT)

In accordance with DOT

Not applicable

# Dihydroergotamine Mesylate Injection

## Safety Data Sheet

### SECTION 15: Regulatory information

#### 15.1. US Federal regulations

No additional information available

#### 15.2. US State regulations

Dihydroergotamine mesilate (6190-39-2)				
U.S. - California - Proposition 65 - Carcinogens List	U.S. - California - Proposition 65 - Developmental Toxicity	U.S. - California - Proposition 65 - Reproductive Toxicity - Female	U.S. - California - Proposition 65 - Reproductive Toxicity - Male	No significant risk level (NSRL)
No	Yes	No	No	

### SECTION 16: Other information

Full text of H-phrases:

Acute Tox. 4 (Dermal)	Acute toxicity (dermal) Category 4
Acute Tox. 4 (Inhalation)	Acute toxicity (inhalation) Category 4
Acute Tox. 4 (Oral)	Acute toxicity (oral) Category 4
Eye Irrit. 2	Serious eye damage/eye irritation Category 2
Repr. 1B	Reproductive toxicity Category 1B
Skin Irrit. 2	Skin corrosion/irritation Category 2
STOT SE 3	Specific target organ toxicity (single exposure) Category 3
H302	Harmful if swallowed
H312	Harmful in contact with skin
H315	Causes skin irritation
H319	Causes serious eye irritation
H332	Harmful if inhaled
H335	May cause respiratory irritation
H360	May damage fertility or the unborn child

*This information is based on our current knowledge and is intended to describe the product for the purposes of health, safety and environmental requirements only. It should not therefore be construed as guaranteeing any specific property of the product.*